Developed by A&D Pharma’s founders, the Ozone business was sold for over €20 mln to the Labormed medication producer this year, owned by the U.S. Advent International investment fund. In fact, the object of this transaction was Ozone’s medication and food supplement brands, so Ozone’s branches in CEE countries were to be integrated in the A&D Pharma business.

According to A&D Pharma estimates, the net sales of acquired companies will contribute by 12 percent to the group’s turnover. The most important condition preceding the finalization of the acquisition was approval by the five-bank consortium, which signed a €100 mln refinancing loan for A&D Pharma early this year.